Gilead Sciences, Inc.
NASDAQ Global SelectTotal Valuation
Gilead Sciences, Inc. carries a market capitalization of 159.50B, placing it among publicly traded companies globally. Its enterprise value stands at 187.68B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 159.50B |
| Enterprise Value | 187.68B |
Share Statistics
Gilead Sciences, Inc. currently has 1.24B shares outstanding.
| Shares Outstanding | 1.24B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Gilead Sciences, Inc. trades at a trailing price-to-earnings ratio of 18.80. The price-to-sales ratio is 5.83, and the price-to-book ratio stands at 12.26.
| PE Ratio | 18.80 |
| PS Ratio | 5.83 |
| PB Ratio | 12.26 |
| P/TBV Ratio | -137.05 |
| P/FCF Ratio | 15.35 |
| P/OCF Ratio | 16.03 |
Enterprise Valuation
On an enterprise value basis, Gilead Sciences, Inc. trades at an EV/EBITDA multiple of 12.81 and an EV/FCF ratio of 15.33. The EV/Sales ratio of 6.31 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 15.77 provides insight into valuation relative to core operating earnings.
| EV / Sales | 6.31 |
| EV / EBITDA | 12.81 |
| EV / EBIT | 15.77 |
| EV / FCF | 15.33 |
Financial Position
Gilead Sciences, Inc. maintains a current ratio of 1.97, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 94.64, indicating elevated leverage, while an interest coverage ratio of 14.58 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.97 |
| Quick Ratio | 1.31 |
| Debt / Equity | 94.64 |
| Debt / EBITDA | 1.51 |
| Interest Coverage | 14.58 |
Financial Efficiency
Gilead Sciences, Inc. posts a return on equity of 73.54 and a return on invested capital of 23.25.
| Return on Equity (ROE) | 73.54 |
| Return on Assets (ROA) | 16.35 |
| Return on Invested Capital (ROIC) | 23.25 |
| Return on Capital Employed (ROCE) | 27.99 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.34 |
Taxes
Over the trailing twelve months, Gilead Sciences, Inc. has paid 1.51B in income taxes, reflecting an effective tax rate of 14.08.
| Income Tax | 1.51B |
| Effective Tax Rate | 14.08 |
Stock Price Statistics
Gilead Sciences, Inc.'s stock has gained approximately 17.50663% over the past 52 weeks. The 50-day moving average sits at 134.71, while the 200-day moving average is 128.75.
| Beta (5Y) | N/A |
| 52-Week Price Change | 17.50663% |
| 50-Day Moving Average | 134.71 |
| 200-Day Moving Average | 128.75 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Gilead Sciences, Inc. generated 29.73B in revenue and converted that into 9.22B in net income, yielding earnings per share of 7.35. EBITDA reached 14.65B, while operating income came in at 11.90B.
| Revenue | 29.73B |
| Gross Profit | 23.60B |
| Operating Income | 11.90B |
| Pretax Income | 10.73B |
| Net Income | 9.22B |
| EBITDA | 14.65B |
| EBIT | 11.90B |
| Earnings Per Share (EPS) | 7.35 |
Balance Sheet
Gilead Sciences, Inc. holds 7.64B in cash and equivalents against 22.17B in total debt, resulting in a net debt position of 14.55B. Total book value stands at 14.13B, with working capital of 9.17B providing operational flexibility.
| Cash & Cash Equivalents | 7.64B |
| Total Debt | 22.17B |
| Net Debt | 14.55B |
| Equity (Book Value) | 14.13B |
| Book Value Per Share | 11.37 |
| Working Capital | 9.17B |
Cash Flow
Gilead Sciences, Inc. produced 10.81B in operating cash flow over the past twelve months. After subtracting -576.00M in capital expenditures, free cash flow totaled 10.23B - equivalent to 8.23 per share.
| Operating Cash Flow | 10.81B |
| Capital Expenditures | -576.00M |
| Free Cash Flow | 10.23B |
| FCF Per Share | 8.23 |
Margins
Gilead Sciences, Inc. operates with a gross margin of 79.35, reflecting its pricing power and cost economics. The operating margin of 40.02 and net profit margin of 30.99 provide insight into operational efficiency.
| Gross Margin | 79.35 |
| Operating Margin | 40.02 |
| Pretax Margin | 36.08 |
| Profit Margin | 30.99 |
| EBITDA Margin | 49.28 |
Dividends & Yields
The company's payout ratio of 43.76 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 3.24 |
| Dividend Yield | N/A |
| Payout Ratio | 43.76 |
| Shareholder Yield | 4.94 |
| FCF Yield | 6.51 |
Stock Splits
Gilead Sciences, Inc.'s most recent stock split took place on January 28, 2013 with a 1:2 split ratio.
| Last Split Date | 1/28/2013 |
| Split Ratio | 1:2 |
Scores
Gilead Sciences, Inc. posts an Altman Z-Score of 6.32, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.32 |